UOC Genetica Medica-Dipartimento di Biomedicina dell'Età Evolutiva-Università di Bari Aldo Moro Azienda, Ospedaliero-Universitaria Policlinico P.zza G. Cesare 11, 70124 Bari, Italy.
Fam Cancer. 2011 Jun;10(2):285-95. doi: 10.1007/s10689-011-9419-0.
Lynch syndrome (LS), or hereditary non-polyposis colorectal cancer (HNPCC), is an autosomal dominant condition responsible for early onset cancer mostly in the colonrectum and endometrium as well as in other organ sites. Lynch syndrome is caused by germline mutations in mismatch repair genes, prevalently in hMSH2, hMLH1, and less frequently in hMSH6 and hPMS2. Twenty-nine non-related index cases with colorectal cancer (CRC) were collected from a region in southeast Italy (Apulia). Among this set of patients, fifteen fulfilled the Amsterdam criteria II. The presence of tumor microsatellite instability (MSI) was assessed in all index cases and 19 (15 AC+/4 AC-) were classified as MSI-H. Mutation analysis performed on all patients, identified 15 pathogenic mutations in hMLH1 and 4 in hMSH2. 4/15 mutations in hMLH1 and 2/4 hMSH2 mutations have not been previously reported. Three previously reported mutations were further investigated for the possibility of a common founder effect. Genetic counseling was offered to all probands and extended to 183 relatives after molecular testing and 85 (46%) mutation carriers were identified. Eighty mutation carriers underwent an accurate clinical and instrumental surveillance protocol. Our results confirm that the identification of LS patients based exclusively on family history may miss patients carrying germline mutations in the MMR genes. Moreover, our results demonstrated that molecular screening and subsequent instrumental surveillance are very effective in identifying CRCs at earlier stages and reducing the number of deaths from secondary cancers in HNPCC patients.
林奇综合征(LS),或遗传性非息肉病性结直肠癌(HNPCC),是一种常染色体显性疾病,主要导致结肠直肠和子宫内膜以及其他器官部位的早期癌症。林奇综合征是由错配修复基因的种系突变引起的,主要是 hMSH2、hMLH1,较少见的是 hMSH6 和 hPMS2。从意大利东南部(普利亚大区)的一个地区收集了 29 名患有结直肠癌(CRC)的非相关索引病例。在这组患者中,有 15 名符合阿姆斯特丹标准 II。所有索引病例均评估肿瘤微卫星不稳定性(MSI),19 例(15 例 AC+/4 例 AC-)被归类为 MSI-H。对所有患者进行突变分析,在 hMLH1 中发现了 15 个致病性突变,在 hMSH2 中发现了 4 个。在 hMLH1 中发现了 4/15 个突变,在 hMSH2 中有 2/4 个突变以前没有报道过。对 3 个以前报道的突变进行了进一步研究,以确定是否存在共同的启动子效应。所有先证者都提供了遗传咨询,并在分子检测后扩展到 183 名亲属,发现了 85 名(46%)突变携带者。80 名突变携带者接受了准确的临床和仪器监测方案。我们的研究结果证实,仅根据家族史识别 LS 患者可能会遗漏携带 MMR 基因突变的患者。此外,我们的研究结果表明,分子筛选和随后的仪器监测在识别 HNPCC 患者的早期 CRC 方面非常有效,并减少了继发癌症导致的死亡人数。